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ABSTRACT
Objective: To assess the usage patterns of epidural
injections for chronic spinal pain in the fee-for-service
(FFS) Medicare population from 2000 to 2014 in the
USA.
Design: A retrospective cohort.
Methods: The descriptive analysis of the administrative
database from Centers for Medicare and Medicaid
Services (CMS) Physician/Supplier Procedure Summary
(PSPS) master data from 2000 to 2014 was performed.
The guidance from Strengthening the Reporting of
Observational studies in Epidemiology (STROBE) was
applied. Analysis included multiple variables based on
the procedures, specialties and geography.
Results: Overall epidural injections increased 99% per
100 000 Medicare beneficiaries with an annual increase
of 5% from 2000 to 2014. Lumbar interlaminar and
caudal epidural injections constituted 36.2% of all
epidural injections, with an overall decrease of 2% and
an annual decrease of 0.2% per 100 000 Medicare
beneficiaries. However, lumbosacral transforaminal
epidural injections increased 609% with an annual
increase of 15% from 2000 to 2014 per 100 000
Medicare population.
Conclusions: Usage of epidural injections increased
from 2000 to 2014, with a decline thereafter. However,
an escalating growth has been seen for lumbosacral
transforaminal epidural injections despite numerous
reports of complications and regulations to curb the
usage of transforaminal epidural injections.
INTRODUCTION
The reports of neurological complications
from epidural injections have taken centre
stage in the USA1–7 and in other parts of the
world over the years.8 Even though the basis
for such alarm and subsequent regulatory
atmosphere has been criticised,4–7 the explo-
sive increase of numerous modalities to
manage spinal pain including epidural injec-
tions and the economic impact have provided
ammunition for such an atmosphere.9–18
Reports from the US Burden of Disease
Collaborators19 and from other parts of the
world20 21 have shown spinal pain occupying
three of the ﬁve top categories of disability.
In addition, the prevalence of chronic
impairing low back pain has increased in
one report 162% from 1992 to 2006, increas-
ing from 3.9% to 10.2%.22 Further, multiple
assessments also have shown the chronicity of
spinal pain long after its onset.23 24 The evi-
dence of increasing burden of disease and
disability across the globe coupled with
increasing numbers of treatments have
created an unacceptable situation with eco-
nomic, social and healthcare impact. Further
complicating this circumstance is the widely
debated issues of efﬁcacy of these interven-
tions.24–40
The statistics show that epidural injections,
including percutaneous adhesiolysis proce-
dures, are the most commonly performed
procedures in managing spinal pain among
interventional techniques, varying from
58.6% in 2000 to 45.2% in 2014 of all
Strengths and limitations of this study
▪ This assessment of usage patterns of epidural
injections has been conducted to describe the
characteristics of all types of epidural injections
in managing chronic spinal pain in the
fee-for-service (FFS) Medicare population in the
USA from 2000 to 2014.
▪ The strengths of this assessment include use of
100% FFS Medicare population including those
above and below 65 years of age.
▪ One of the limitations is that the study is
restricted to only the Medicare population and
patients with Medicare Advantage plans have not
been included which constitute between 20%
and 30% of the population.
▪ Additionally, while these results can be general-
ised to a great extent, caution must be exercised
since in other population groups the usage
might be materially different.
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interventional techniques.15 The usage of epidural pro-
cedures, excluding percutaneous adhesiolysis, showed an
overall increase of 165% or 96% per 100 000
fee-for-service (FFS) Medicare beneﬁciaries with an
annual increase of 7.2% or 4.9% from 2000 to 201415
showing a slight decrease compared to 2000 to 2013,
from a rate of 105.6% to an annual increase of 5.7%.
Interlaminar epidural injections have increased at a
slower pace. Among the epidural injections, continuous
epidural injections with catheterisation and neurolytic
epidural procedures have not been used in managing
chronic spinal pain. Manchikanti et al,11–14 in assessing
Medicare FFS population in the USA from 2000 to 2013,
showed an increase of 119% for cervical and thoracic
interlaminar epidural injections and 11% for lumbosa-
cral interlaminar and caudal epidural injections per
100 000 Medicare population with an annual increase of
6.2% or 0.8%, respectively. Contrasting these milder
increases, they determined an explosive increase of
577% for lumbosacral transforaminal epidural injections
and an 84% increase of cervical and thoracic transfor-
aminal epidural injections per 100 000 Medicare popula-
tion with an annual increase of 15.8% and 4.8%,
respectively, during the same period.11 12 14 Thus, the
use of epidural injections has risen dramatically, despite
discordant opinions of their effectiveness and their asso-
ciation with rare, but catastrophic complications.24–44
This study is undertaken with an aim of assessing the
usage patterns and patterns of use of epidural injections
in Medicare FFS population in the USA with the analysis
of data from 2000 to 2014.
METHODS
Approval by the Institutional Review Board (IRB) was
not sought for this assessment as all analysis encom-
passed public use ﬁles (PUF) or non-identiﬁable data,
which is non-attributable and non-conﬁdential, available
through the Centers for Medicare and Medicaid
Services (CMS) database.45 The study was performed
using Strengthening the Reporting of Observational
studies in Epidemiology (STROBE) guidance.46
Study design
The study was designed to assess usage patterns of epi-
dural injections, excluding continuous epidurals and
neurolytic procedures, which constitute a small propor-
tion used for chronic management, in the FFS Medicare
population in the USA from 2000 to 2014.
Setting
National database of specialty usage data ﬁles from CMS,
USA, FFS Medicare.45
Participants
Participants included the FFS Medicare recipients from
2000 to 2014.
For analysis, the current procedure codes for epidural
injections were used. The CPT codes used included epi-
dural codes CPT 62310, 62311 and transforaminal epi-
dural codes CPT 64479, 64480, 64483 and 64484. These
codes were identiﬁed for years 2000 to 2014.
Subsequently, usage data were assessed based on the
place of service, either the facility which included ambu-
latory surgery centres and hospital outpatient depart-
ments (HOPDs), or a non-facility setting—the ofﬁce.
The data are calculated for overall services for each tech-
nique, and the rate of services for 100 000 Medicare
beneﬁciaries, and also based on the specialty.
Variables
Multiple characteristics are assessed in this evaluation of
the Medicare population and increase in the Medicare
population from 2000 to 2014, usage of epidural proce-
dures in the cervical, thoracic, lumbar and sacral spine.
Additional characteristics assessed included various spe-
cialty designations and the settings in which the proce-
dures were performed.
The description of various specialties was as follows: mul-
tiple specialties representing interventional pain physicians
including interventional pain management −09, pain
medicine −72, anaesthesiology −05, physical medicine and
rehabilitation −25, neurology −13, psychiatry −26 were
described as interventional pain management. Surgical
specialties included orthopaedic surgery −20, general
surgery −17 and neurosurgery −14. Radiologic specialties
included diagnostic radiology −30 and −94 interventional
radiology. All other physicians were grouped into a separate
group (general physicians), and all other non-physician
providers were considered as other providers.
Data sources
The data were obtained from the CMS physician sup-
plier procedure summary master data from 2000
through 2014.45 These data provide all FFS Medicare
participants below the age of 65 and above the age of 65
receiving epidural procedures.
Measures
Allowed services were calculated from services submitted
minus services denied and services with zero payments.
Allowed services were assessed for each procedure,
and rates were calculated based on Medicare beneﬁciar-
ies for the corresponding year and are reported as pro-
cedures per 100 000 Medicare beneﬁciaries.
Bias
The study was conducted with the internal resources of
the primary author’s practice without any external
funding, either from industry or elsewhere. The data
were purchased from CMS by the American Society of
Interventional Pain Physicians (ASIPP). CMS’s 100%
data set consists of usage by CPT code with modiﬁer
usage (as an additional procedure or bilateral proced-
ure), specialty codes, place of service, Medicare carrier
2 Manchikanti L, et al. BMJ Open 2016;6:e013042. doi:10.1136/bmjopen-2016-013042
Open Access
number, total services and charges submitted, allowed
and denied, and amount paid.
Study size
The study size is large with inclusion of all patients
under Medicare FFS undergoing epidural procedures
for spinal pain from 2000 to 2014.
Data compilation
The data were compiled using Microsoft Access 2003
and Microsoft Excel 2003 (Microsoft, Redmond,
Washington, USA).
RESULTS
Participants
Participants included the FFS Medicare recipients from
2000 to 2014.
Descriptive data
Table 1 illustrates the characteristics of Medicare beneﬁ-
ciaries as well as the epidural injections provided to
them. Medicare beneﬁciaries increased 35% from 2000
to 2014 compared to an increase of 99% in the rate
(per 100 000 Medicare beneﬁciaries) of epidural injec-
tions with an annual increase of 5% compared to a 2.2%
annual increase in the number of Medicare beneﬁciaries
which is 2.6 times the increase of the population rate.
Usage characteristics
Table 2 and ﬁgure 1 illustrate the usage characteristics
of epidural injections in the Medicare population from
2000 to 2014. Overall epidural injections increased 99%
per 100 000 Medicare beneﬁciaries with an annual
increase of 5%. However, lumbosacral interlaminar and
caudal epidural injections (CPT 62311) decreased 2%
per 100 000 Medicare beneﬁciaries with a 0.2% annual
decrease compared to an increase of 104% per 100 000
beneﬁciaries and a 5.2% annual increase for cervical/
thoracic interlaminar epidural injections (CPT 62310).
In contrast, lumbosacral transforaminal epidural injec-
tions (CPT 64483 and 64484) increased 609% per
100 000 population with an annual increase of 15% and
cervical/thoracic transforaminal epidural injections
(CPT 64479 and 64480) increased 93% with an annual
increase of 4.8%. Thus, all the decrease in usage of
interlaminar epidural injections were compensated by
increases of transforaminal epidural injections in the
lumbar spine. In addition, cervical and thoracic transfor-
aminal epidural injections have been decreasing from
2011 to 2013 but have shown an increase in 2014. Using
the number of patient episodes providing the services,
lumbar/sacral interlaminar or caudal epidural injections
(CPT 62311) decreased at a rate of −2% from 2000 to
2014, whereas the rate of usage in 2014 was 815 858 ser-
vices with 1525 per 100 000 Medicare FFS population
with a decrease of 12.2% from the previous year and the
decreases observed from 2006 through 2014. In
addition, the number of patient episodes with transfor-
aminal epidural injections (CPT 64483) were slightly less
with 763 793 services with 1428 per 100 000 Medicare
population, with an increase of 15% from 2000 to 2014,
with decreases observed in 2 years with 4.0% decrease in
2012 and 5.1% in 2013 with an increase of 4.7% in
2014. In 2000, 1560 patients per 100 000 Medicare popu-
lation received lumbar and caudal epidural injections,
whereas 214 received lumbar transforaminal epidural
injections. These numbers decreased for interlaminar
epidural injections from 1560 to 1525, whereas lumbar
transforaminal epidural injections increased from 214 to
1428 per 100 000 Medicare population.
As shown in ﬁgure 2, the proportion of epidural injec-
tions of all interventional techniques performed
reduced 57% to 45% from 2000 to 2014.
Specialty characteristics
Online supplementary appendices 1 and 2 illustrate the
usage of epidural injections by various specialties. In the
group of interventional pain management, including
anaesthesiology, interventional pain management, pain
medicine, physical medicine and rehabilitation, neur-
ology and psychiatry, the rate of increase was 113% per
100 000 Medicare beneﬁciaries with an overall increase
of 99% from 2000 to 2014. However, among these
groups, physical medicine and rehabilitation showed an
overall increase of 672% and 472% per 100 000
Medicare beneﬁciaries. Radiology, consisting of interven-
tional radiology and diagnostic radiology, also showed an
increasing rate of 167% per 100 000 Medicare beneﬁ-
ciaries from 2000 to 2014. Surgical specialties, including
neurosurgery, orthopaedic surgery and general surgery,
showed an increase of 58% from 2000 to 2014.
Site of service characteristics
Epidural injections are provided in multiple settings includ-
ing HOPDs, ambulatory surgical centres (ASCs) and in phy-
sician’s ofﬁces (in-ofﬁce). There has been a signiﬁcant shift
over the years in epidural injections based on the location of
the procedure’s performance. In 2002, HOPD services con-
stituted 54.3%, with ASCs providing 19.9% of the service,
and in-ofﬁce providing 25.8%. By 2014, the HOPD share
decreased to 29.4%, the ASC share increased to 27.7% and
the in-ofﬁce share dramatically increased to 42.9% as shown
in online supplementary appendices 3 and 4.
Main results
▸ Epidural injections increased 99% per 100 000
Medicare beneﬁciaries with an annual increase of 5%
in FFS Medicare beneﬁciaries from 2000 to 2014.
Lumbar interlaminar and caudal epidural injections
constituted 36.2% of all epidural injections, with an
overall decrease of 2% and an annual decrease of
0.2% per 100 000 Medicare beneﬁciaries.
▸ Lumbosacral transforaminal epidural injections
increased 609% with an annual increase of 15% from
2000 to 2014 per 100 000 Medicare population.
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Table 1 Characteristics of Medicare beneficiaries and epidural procedures excluding percutaneous adhesiolysis, continuous epidurals and neurolytic epidurals.
US population Medicare beneficiaries Epidural services*
≥65 years (,000)
Total population
(,000) Number Per cent
Number
(,000)
Per cent to US
population
≥65 years
(,000) (%)
<65 years
(,000) % Services*
Per cent of change
from previous year
Per 100 000 Medicare FFS
enrollees
Per cent of change
from previous year
Y2000 282 172 35 077 12.4 39 632 14.0 34 262 (86.5%) 5370 (13.5%) 839 474 (80%) NA 2118 –
Y2001 285 040 35 332 12.4 40 045 14.0 34 478 (86.1%) 5567 (13.9%) 989 034 (78%) 17.8 2470 16.6
Y2002 288 369 35 605 12.3 40 503 14.0 34 698 (85.7%) 5805 (14.3%) 1 172 248 (74%) 18.5 2894 17.2
Y2003 290 211 35 952 12.4 41 126 14.2 35 050 (85.2%) 6078 (14.8%) 1 342 829 (71%) 14.6 3265 12.8
Y2004 292 892 36 302 12.4 41 729 14.2 35 328 (84.7%) 6402 (15.3%) 1 611 887 (65%) 20.0 3863 18.3
Y2005 295 561 36 752 12.4 42 496 14.4 35 777 (84.2%) 6723 (15.8%) 1 747 771 (65%) 8.4 4113 6.5
Y2006 299 395 37 264 12.4 43 339 14.5 36 317 (83.8%) 7022 (16.2%) 1 844 182 (63%) 5.5 4255 3.5
Y2007 301 290 37 942 12.6 44 263 14.7 36 966 (83.5%) 7297 (16.5%) 1 915 227 (62%) 3.9 4327 1.7
Y2008 304 056 38 870 12.8 45 412 14.9 37 896 (83.4%) 7516 (16.6%) 2 017 132 (61%) 5.3 4442 2.7
Y2009 307 006 39 570 12.9 45 801 14.9 38 177 (83.4%) 7624 (16.6%) 2 112 511 (59%) 4.7 4612 3.8
Y2010 308 746 40 268 13.0 46 914 15.2 38 991 (83.1%) 7923 (16.9%) 2 205 307 (57%) 4.4 4701 1.9
Y2011 311 583 41 370 13.3 48 300 15.5 40 000 (82.8%) 8300 (17.2%) 2 289 213 (58%) 3.8 4740 0.8
Y2012 313 874 43 144 13.8 50 300 16.0 41 900 (83.3%) 8500 (16.9%) 2 304 993 (58%) 0.7 4582 −3.3
Y2013 316 129 44 704 14.1 51 900 16.4 43 100 (83.0%) 8800 (17.0%) 2 259 887 (58%) −2.0 4354 −5.0
Y2014 318 892 46 179 14.5 53 500 16.8 44 600 (83.4%) 8900 (16.5%) 2 255 668 (57%) −0.2 4216 −3.2
Per cent
change from
2000 to 2014
13.0 31.7 16.8 35.0 19.8 30.2 65.7 168.7 – 99.0
Geometric
average
change %)
0.9 2.0 2.2 1.9 3.7 7.3 – 5.0
*Epidural services=62310—cervical/thoracic interlaminar epidural injections; 62311—lumbar/sacral interlaminar epidural injections; 64479—cervical/thoracic transforaminal epidural injections;
64480—cervical/thoracic transforaminal epidural injections add-on; 64483—lumbar/sacral transforaminal epidural injections; 64484—lumbar/sacral transforaminal epidural injections add-on.
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Table 2 Utilisations of epidural injections in the fee-for-service Medicare population from 2000 to 2014
Cervical/thoracic interlaminar
epidurals (CPT 62310)
Lumbar interlaminar and caudal
epidurals (CPT 62311) Cervical/thoracic transforaminal epidurals Lumbar/sacral transforaminal epidurals
Services Rate
Per cent of change
from previous year Services Rate
Per cent of change
from previous year
CPT
64479
CPT
64480 Total
Rate
Per cent of
change from
previous year
CPT
64483
CPT
64484 Total Per cent of change
from previous yearServices Services Services Services Services Services Rate
2000 75 741 191 – 618 362 1560 – 13 454 9434 22 888 58 – 85 006 37 477 122 483 309 –
2001 84 385 211 10.3 702 713 1755 12.5 14 732 8537 23 269 58 0.6 125 534 53 133 178 667 446 44.4
2002 99 117 245 16.1 786 919 1943 10.7 18 583 10 835 29 418 73 25.0 177 679 79 115 256 794 634 42.1
2003 109 783 267 9.1 838 858 2040 5.0 21 882 15 769 37 651 92 26.0 242 491 114 046 356 537 867 36.7
2004 130 649 313 17.3 878 174 2104 3.2 25 182 18 094 43 276 104 13.3 363 744 196 044 559 788 1341 54.7
2005 141 652 333 6.5 945 350 2225 5.7 27 844 20 525 48 369 114 9.8 395 508 216 892 612 400 1441 7.4
2006 146 748 339 1.6 946 961 2185 −1.8 29 822 23 073 52 895 122 7.2 452 125 245 453 697 578 1610 11.7
2007 156 415 353 4.4 926 029 2092 −4.3 29 938 22 266 52 204 118 −3.4 506 274 274 305 780 579 1764 9.6
2008 165 636 365 3.2 905 419 1994 −4.7 32 286 24 003 56 289 124 5.1 572 340 317 448 889 788 1959 11.1
2009 175 503 383 5.1 888 166 1939 −2.7 37 012 27 487 64 499 141 13.6 632 658 351 685 984 343 2149 9.7
2010 184 750 394 2.8 888 421 1894 −2.3 40 003 29 888 69 891 149 5.8 679 117 383 128 1 062 245 2264 5.4
2011 200 134 414 5.2 914 324 1893 0.0 38 970 26 628 65 598 136 −8.8 710 638 398 519 1 109 157 2296 1.4
2012 213 390 424 2.4 925 179 1839 −2.8 35 945 21 293 57 238 114 −16.2 718 437 390 749 1 109 186 2205 −4.0
2013 217 393 419 −1.3 901 468 1737 −5.6 34 699 20 409 55 108 106 −6.7 700 820 385 098 1 085 918 2092 −5.1
2014 208 741 390 −6.9 815 858 1525 −12.2 37 944 21 587 59 531 111 4.8 763 793 407 745 1 171 538 2190 4.7
Per cent of change from 2000 to 2014
Change 176 104 – 32 −2 – 182 129 160 93 – 799 988 856 609 –
Geometric average annual change (%)
Geometric average 7.5 5.2 – 2.0 −0.2 – 7.7 6.1 7.1 4.8 – 17.0 18.6 17.5 15.0 –
Rate—per 100 000 Medicare beneficiaries.
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However, the ratio of lumbosacral transforaminal epi-
dural injections increased from 14.6% of all epidural
injection in 2000 to 51.9% in 2014, thus, exceeding
interlaminar epidural injections.
▸ Site-of-service usage patterns showed a decrease in
HOPDs associated with a dramatic increase in
in-ofﬁce procedures.
DISCUSSION
Usage of epidural injections for chronic spinal pain in
the FFS Medicare population in the USA increased
dramatically from 2000 to 2014. The increase for epi-
dural injections has been shown to be 99% per 100 000
Medicare beneﬁciaries with an annual increase of 5%,
compared to the increase of Medicare beneﬁciaries per
100 000 population of 35% with an annual increase of
2.2% during the same period. The increases were pre-
dominantly noted for lumbar transforaminal epidural
injections with a 609% increase per 100 000 Medicare
population from 2000 to 2014 with an annual increase
of 15.0%. The increases were modest with 93% for cer-
vical and thoracic transforaminal epidural injections and
104% for cervical and thoracic interlaminar epidural
Figure 1 Frequency of usage of epidural injections by procedures from 2000 to 2014, in Medicare recipients.
Figure 2 Frequency of usage of epidural injections and all other interventional pain management procedures from 2000 to
2014, in Medicare recipients.
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injections per 100 000 Medicare population. Usage of
cervical/thoracic interlaminar epidural injections
decreased by 6.9%, from 217 393 to 208 741, from 2013
to 2014 and for lumbar/sacral interlaminar epidural
injections 9% from 901 468 to 815 858, whereas there
was an 8% increase in cervical/thoracic transforaminal
epidural injections from 55 108 to 59 531 and an 8%
increase in lumbar/sacral transforaminal epidural injec-
tions from 1 085 918 to 1 171 538. Dramatic increases
were noted for lumbosacral transforaminal epidural
injections from a baseline rate of 309 in 2000 to 2190 in
2014 for per 100 000 Medicare population, an increase
of 609% or an annual rate of 15%. In contrast, interla-
minar epidural injections in the lumbar spine, which
also include caudal epidural injections, have decreased
2% with an annual decrease of 0.2% from 1560 in 2000
per 100 000 Medicare population to 1525 in 2014.
Consequently, only interlaminar epidural injections cor-
related with overall Medicare beneﬁciary growth, which
has been shown to be 35% and growth of Medicare
beneﬁciaries above age 65 years vs below 65 years with
30.2% vs 65.7%. There was also change in site of service
usage patterns with a decrease in HOPD use and a dra-
matic increase in in-ofﬁce services. ASC share increased
from 19.9% in 2002 to 27.7% in 2014 and in-ofﬁce ser-
vices dramatically increased from 25.8% in 2002 to
42.9% in 2014 (see online supplementary appendices 3
and 4), whereas HOPD share decreased from 54.3% to
29.4%.
As shown in online supplementary appendices 2 and
3, specialty characteristics showed that an overwhelming
majority of the procedures (89.5%) were performed by
pain management specialists, which essentially remained
stable over the years. Surgery was a distant second spe-
cialty with 4.5% and radiology followed with 3.8% usage.
Surgical specialties performed fewer procedures when
compared to 2000, whereas radiologists performed more
procedures. General physicians and other providers
including Certiﬁed Registered Nurse Anesthetists, nurse
practitioners and Physician Assistants also provided a
lesser number of epidural injections than in 2000.
The results demonstrated in this evaluation were
similar to other recently performed evaluations.11–15
However, these results are noteworthy compared to
some of the previous studies, which focused on different
aspects rather than assessment of growth and usage.47–49
Friedly et al47 48 and Abbott et al49 indicate that injection
therapies were provided with lack of evidence for man-
aging chronic low back pain. Abbott et al49 also included
analysis of a publication from the Ofﬁce of Inspector
General in 201050 with multiple recommendations to
curb the growth of lumbosacral transforaminal epidurals
that showed a lack of signiﬁcant effect or, at most, mild
inﬂuence. Another paradoxical development is that
transforaminal epidural injections have exceeded the
total number of lumbar interlaminar and caudal epi-
dural injections starting in 2009, which essentially
reversed a long-standing trend of a high proportion of
interlaminar and caudal epidural injections compared
to transforaminal epidural injections, despite multiple
reports of complications and resultant warnings.1–5 11–15
Some of the limitations for our assessment include
lack of inclusion of patients participating in Medicare
Advantage Plans, which could lead to exclusion of ∼20–
30% of the population. Further, there is also potential
for coding errors and elimination of procedures which
are not commonly used for spinal pain, such as continu-
ous epidural injections and neurolytic procedures, may
underestimate the number of procedures performed.
However, the advantages of this study include that we
have used the full Medicare data instead of an extrapola-
tion and also all Medicare FFS population instead of
using only those 65 years or older.
The increasing prevalence, disability, healthcare costs
and human toll of spinal pain, the increasing usage of
all modalities, speciﬁcally epidural injections—the
subject of this assessment—continue to incite contro-
versy and provide the basis of the claims that epidural
injections are overused, leading to inappropriate use,
abuse and fraud without evidence of efﬁcacy, medical
necessity and indications.12 24–26 37 38 The supporters of
various modalities continue to profess cautious use with
demonstration of effectiveness and cost utility, claim
that spinal pain continues to increase, along with its
understanding, which continues to evolve over the
years.24–36 39 40 51 Thus, epidural injections in managing
chronic spinal pain are justiﬁed with moderate evidence
available in support of these injections in appropriately
conducted randomised trials and systematic
reviews.12 24–26 37 38 51 However, others have provided
contradictory evidence with lack of effectiveness demon-
strated in high-proﬁle assessments.25 26 37 These reports
have been extensively critiqued.24 27–32 52–56 In addition
to substantial differences between proponents and oppo-
nents with the majority of the government-sponsored
studies in the USA showing lack of effectiveness of
epidural injections in managing low back and lower
extremity pain, Lewis et al39 40 in two separate manu-
scripts funded by the National Health Services (NHS)
and health technology assessment programme have pre-
sented positive results for epidural injections. In a sys-
tematic review and economic model of the clinical and
cost-effectiveness of management strategies for sciatica
performed for the health technology assessment,39 results
were positive for demonstrating the effectiveness of epi-
dural corticosteroid injections. They40 also showed, in a
systematic review and network meta-analysis of compara-
tive clinical effectiveness of management strategies for sci-
atica with review of 122 relevant studies and 21 treatment
strategies, statistically signiﬁcant improvement with epi-
dural injections. In addition, network meta-analysis40 also
showed superiority of epidural injections to traction,
percutaneous discectomy and exercise therapy.
Overall, this assessment shows a continued increase of
usage from 2000 to 2011, with subsequent decreasing
patterns of usage of epidural injections. However,
Manchikanti L, et al. BMJ Open 2016;6:e013042. doi:10.1136/bmjopen-2016-013042 7
Open Access
large-scale and seemingly inappropriate increases in
usage are related to lumbar transforaminal epidural
injections, whereas there was a net decrease of lumbar
interlaminar and caudal epidural injections. Even
though epidural injections have constituted smaller
increases when compared to other modalities, with con-
tinued controversy and the increase of 609% in lumbosa-
cral transforaminal epidural injections from 2000 to
2014, and associated major complications related to
transforaminal epidural injections, caution must be
exercised in performing these procedures, speciﬁcally
transforaminal epidural injections. Thus, it is essential
not only to develop appropriate evidence, but also to
synthesise the evidence using up-to-date randomised
controlled trials and proper methodology without
conﬂuence of bias. With such analysis of the data, there
is no superiority for transforaminal epidural injections
compared to interlaminar epidural injections in the
lumbar or cervical spine.24 27 29 30 32 57 58
CONCLUSIONS
The use of epidural injections escalated from 2000 to
2011 with a small decline since then. However, dramatic
increases were shown in usage patterns of lumbar trans-
foraminal epidural injections despite rare complications,
warnings and measures reducing the overall impact.
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